Biogen (BIIB) Change in Accured Expenses (2009 - 2026)

Biogen's Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$243.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 19.07% year-over-year to -$243.2 million; the TTM figure through Mar 2026 stood at -$190.7 million (up 36.88% YoY), while the FY2025 annual figure was -$248.0 million, down 38.78% from the prior year.
• Change in Accured Expenses was -$243.2 million for Q1 2026 at Biogen, down from -$215.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.1 billion in Q2 2022 to a low of -$745.7 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged -$57.9 million across 5 years, with a median of -$94.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses plunged 854.76% in 2022, then jumped 24864.71% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$745.7 million in 2022, then jumped by 33.55% to -$495.5 million in 2023, then surged by 80.93% to -$94.5 million in 2024, then sank by 127.83% to -$215.3 million in 2025, then declined by 12.96% to -$243.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$243.2 million (Q1 2026), -$215.3 million (Q4 2025), and $286.0 million (Q3 2025), per Business Quant data.